-
@CureMatch CEO,@StephR1chard discusses how to bridge the gap between academia and patient care providers#JLABSAlumni pic.twitter.com/wrBUtZPS6R
-
Very exciting company in rapidly advancing CAR-T space.
#JLABSAlumni https://twitter.com/melindarichter/status/1021807498259353600 … -
So fun visiting
#JLABSAlumni@ArcturusRx today! So cool to see where the Arcturus magic happens
and your growth & accomplishments since your @JLABS days!
pic.twitter.com/PhrbCa7jmL
-
Personalization is
#JLABSAlumni @myskinstatic shares how they use tech + science to create skincare products based on ethnicity, skin type, age & more#femtech#JLABSSD@AthenaSanDiegopic.twitter.com/pjdqYjFkWB
-
Last up,
@gracesoyao from@sccatalysts#JLABSAlumni shares how patients are driving health innovation & how their software is using#AI and#blockchain#JLABSToronto#Spotlightpic.twitter.com/pw81QjYZaM
-
“Each cancer is like a snowflake – complex and unique” – Dr. Kurzrock, founder of
@CureMatch, a#JLABSAlumni that has just announced a partnership to bring their#precisionmedicine platform to oncologists around the world https://jlabs.tv/2O12mx5 -
@ArcturusRx on the rise by entering a research collaboration with Synthetic Genomics#JLABSalumni https://jlabs.tv/2z1On5i -
Let’s celebrate
#JLABSSD entrepreneurs@LynxBio@DTxPharma@StephJCuller of Persephone Biome &#JLABSAlumni Singular Genomics, winners of the@BiocomCA Life Science Catalyst Award!@JLABS https://jlabs.tv/2OhHlgV -
#JLABSAlumni@PoseidaThera announces expanded partnership to advance development of their next-gen CAR-T therapies#JLABSSD https://jlabs.tv/2vPaRmk pic.twitter.com/4jmVBlYwWe
-
#JLABSAlumni Amplyx raised $67M in a Series C led by Sofinnova Venture Partners to advance new anti-fungal drug http://jlabs.tv/2hnqQE5 -
@ArcturusRx to merge with@AlcobraPharma to become the 4th#JLABSSD company to go public#JLABSalumni#mycompany http://jlabs.tv/2xIKDEh -
#JLABSAlumni@CureMatch CEO shares how San Diego’s rich startup ecosystem has helped shape his company that focuses on#precisionmedicine in oncology@SDRegionalEDC@DawnBarryDNApic.twitter.com/FE9Y6Nd4m0
-
#JLABSAlumni@MiratiTx reports data from Phase II trial for RET inhibitor + a jump in their stock price http://jlabs.tv/2wr2oco#JLABSSD -
New research agreement for
#JLABSAlumni Arcturus to advance novel therapeutic for#cysticfibrosis@pad_arcturusrx http://jlabs.tv/2rlfm7r -
Starting 2018 off right -
#JLABSAlumni@BatuBiologics secures $1.3M in equity crowdfunding for their tumor-angiogenesis targeting immunotherapy http://jlabs.tv/2CflKQA#JLABSSD#mycompany -
Thank you
@BritSab09 nice to see you at the@SDRegionalEDC launch of the#PrecisionHealthSD initiative. Always glad to represent as part of the#JLABSAlumni https://twitter.com/BritSab09/status/1067970927940448256 …
-
Wishing the best to Jecure Therapeutics & Ideaya Biosciences! now
#JLABSAlumni#JLABSSDpic.twitter.com/kO13J9wEWO
-
#JLABSSD alumni@ArcturusRx announces expansion of a collaboration to develop RNA-based therapeutics to treat NASH & GI disorders#JLABSAlumni http://jlabs.tv/2Dp2uEJ -
One of
#JLABSSD's first 5 residents,@Renascions is sharing the latest progress on their science#JLABSAlumni#oncologypic.twitter.com/94EsQtfNuI
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.